Vaccination Two typhoid vaccines are licensed for use in the prevention of typhoid: the live, oral Ty21a vaccine (sold as Vivotif by Crucell Switzerland AG) and the injectable typhoid polysaccharide vaccine (sold as Typhim Vi by Sanofi Pasteur and Typherix by GlaxoSmithKline). Both are efficacious and recommended for travelers to areas where typhoid is endemic. Boosters are recommended every five years for the oral vaccine and every two years for the injectable form. An older, killed whole-cell vaccine is still used in countries where the newer preparations are not available, but this vaccine is no longer recommended for use because it has more side effects (mainly pain and inflammation at the site of the injection). thumbtime=1:00|thumb|Vivotif – oral typhoid vaccine of live-attenuated S. enterica Typhi strain Ty21a To help decrease rates of typhoid fever in developing nations, the World Health Organization (WHO) endorsed the use of a vaccination program starting in 1999. Vaccination has proven effective at controlling outbreaks in high-incidence areas and is also very cost-effective: prices are normally less than US$1 per dose. Because the price is low, poverty-stricken communities are more willing to take advantage of the vaccinations. Although vaccination programs for typhoid have proven effective, they alone cannot eliminate typhoid fever. Combining vaccines with public health efforts is the only proven way to control this disease.
vaccination two typhoid vaccines are licensed for use in the prevention of typhoid the live oral ty21a vaccine (sold as vivotif by crucell switzerland ag) and the injectable typhoid polysaccharide vaccine (sold as typhim vi by sanofi pasteur and typherix by glaxosmithkline) both are efficacious and recommended for travelers to areas where typhoid is endemic boosters are recommended every five years for the oral vaccine and every two years for the injectable form an older killed whole-cell vaccine is still used in countries where the newer preparations are not available but this vaccine is no longer recommended for use because it has more side effects (mainly pain and inflammation at the site of the injection) thumbtime=100|thumb|vivotif – oral typhoid vaccine of live-attenuated s enterica typhi strain ty21a to help decrease rates of typhoid fever in developing nations the world health organization (who) endorsed the use of a vaccination program starting in 1999 vaccination has proven effective at controlling outbreaks in high-incidence areas and is also very cost-effective prices are normally less than us$1 per dose because the price is low poverty-stricken communities are more willing to take advantage of the vaccinations although vaccination programs for typhoid have proven effective they alone cannot eliminate typhoid fever combining vaccines with public health efforts is the only proven way to control this disease